Futura Medical PLC's (LON:FUM) Ken James speaks to Proactive London's Andrew Scott after announcing it's submitted the product dossier for its treatment of erectile dysfunction known as MED3000 for marketing approval in Europe. In the US, James says that after a second pre-submission meeting with the US Food and Drug Administration (FDA), a pathway to US marketing approval for MED3000 has been established.
Futura Medical's Ken James updates on EU and US regulatory progress for MED3000
Quick facts: Futura Medical PLC
Price: 14.5 GBX
Market Cap: £35.62 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...FOR OUR FULL DISCLAIMER CLICK HERE